Frequency of High Blood Pressure and Dyslipidemia in T1D and T2D—Results from the International Diabetes Management Practices Study (IDMPS)
Authors: GAGLIARDINO JUAN J. , ASCHNER PABLO , ILKOVA HASAN M. , LAVALLE-GONZALEZ FERNANDO J. , RAMACHANDRAN AMBADY , KADDAHA GHAIDA , MBANYA JEAN CLAUDE , SHESTAKOVA MARINA V. , CHANTELOT JEAN-MARC , CHAN JULIANA C. 
Published: June 2018

Appropriate disease management for people with diabetes requires control of not only blood glucose levels but also blood pressure and serum lipid profiles.
The International Diabetes Management Practices Study (IDMPS) is a global observational survey on the management and patterns of care of people with type 1 (T1D) and type 2 (T2D) diabetes in the developing world. We report the proportions of people with high blood pressure (HBP) and abnormal lipid profiles (LDL-C &gt;100 mg/dL) associated with their diabetes in 2016-17 in 24 countries across Africa, the Middle East, South Asia, and Eurasia.
In people with T1D (N=2000), 20% and 30% had HBP and abnormal lipid profiles, respectively (Table). All were prescribed corrective therapy; however, target levels were only achieved by 50% of people. In people with T2D (N=6283), the frequency of both HBP and abnormal lipid profiles increased over time; control of these complications was worse than in T1D. Overall, less than 5% of people with T1D and T2D achieved the triple target of HbA1c &lt;7%, BP &lt;130/80 mmHg, and LDL-C &lt;100 mg/dL.
Many individuals, particularly those with T2D, have concomitant HBP and lipid abnormalities, which add to the burden of disease and complicate management.

Disclosure
J.J. Gagliardino: Other Relationship; Self; Sanofi. P. Aschner: Other Relationship; Self; Sanofi. H.M. Ilkova: Advisory Panel; Self; Abbott, Eli Lilly and Company, Novartis AG, Novo Nordisk A/S, Boehringer Ingelheim GmbH, Servier, Merck Sharp & Dohme Corp.. Speaker's Bureau; Self; AstraZeneca. Advisory Panel; Self; Medtronic, Roche Diabetes Care Health and Digital Solutions, Bilim İlac. F.J. Lavalle-Gonzalez: Advisory Panel; Self; Sanofi. Speaker's Bureau; Self; Sanofi. Research Support; Self; Janssen Pharmaceuticals, Inc.. Advisory Panel; Self; Janssen Pharmaceuticals, Inc.. Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc.. Consultant; Self; Novo Nordisk Inc.. Advisory Panel; Self; AstraZeneca. Speaker's Bureau; Self; AstraZeneca. Research Support; Self; AstraZeneca. Advisory Panel; Self; Merck Sharp & Dohme Corp.. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Advisory Panel; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company. Advisory Panel; Self; Abbott. Speaker's Bureau; Self; Abbott. A. Ramachandran: None. G. Kaddaha: Other Relationship; Self; Sanofi. J. Mbanya: Advisory Panel; Self; GlaxoSmithKline plc.. Speaker's Bureau; Self; Novo Nordisk A/S, Sanofi, Servier. M.V. Shestakova: None. J. Chantelot: Employee; Self; Sanofi. Stock/Shareholder; Self; Sanofi. J.C. Chan: Consultant; Self; Bayer AG. Other Relationship; Self; Bayer AG. Consultant; Self; Sanofi. Other Relationship; Self; Sanofi, Eli Lilly and Company, Amgen Inc.. Consultant; Self; AstraZeneca, Merck & Co., Inc., Pfizer Inc.. Other Relationship; Self; Pfizer Inc.. Board Member; Self; Asia Diabetes Foundation. Stock/Shareholder; Self; GemVCare. Other Relationship; Self; Merck Sharp & Dohme Corp.. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Novartis AG, Eli Lilly and Company.